TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2207297
Drug: Recainam (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recainam (i.v. doses in rats and rabbits)
Study: 2207297
Drug: Recainam (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recainam (i.v. doses in dogs, rhesus monkeys, and humans)
Study: 30900152
Drug: Topically-administered haemocoagulase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically-administered haemocoagulase (batroxobin)
Study: 27837415
Drug: Sexual intercourse
Normalized name: Zinc Gluconate 50 mg ORAL CAPSULE [Pegasus Male Sexual Enhancer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sexual intercourse 3-4 times/week with symptomatic treatment
Study: 27837415
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment only (control group)
Study: 25885280
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg risedronate orally, once a week for 6 months postoperatively
Study: 23313145
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for prescription opioid dependence
Study: 9925129
Drug: Ergocalciferol supplement
Normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ergocalciferol supplement providing 14 microg/d
Study: 27265880
Drug: Mirabegron (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron (50 mg per day) for 8 weeks
Study: 27265880
Drug: Imidafenacin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidafenacin (0.2 mg per day) for 8 weeks
Study: 24980414
Drug: Circumcision plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circumcision plus antibiotic, anti-inflammatory, and α-blocker therapy
Study: 24980414
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (medications only, no circumcision)
Study: 19235739
Drug: Olfactory training
Normalized name: BOS TAURUS OLFACTORY BULB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olfactory training (12 weeks, twice daily exposure to four odors: phenyl ethyl alcohol, eucalyptol, citronellal, eugenol)
Study: 17008974
Drug: Orbofiban (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orbofiban (oral glycoprotein IIb/IIIa inhibitor)
Study: 10761167
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg PO QD for 10 days
Study: 6364909
Drug: Chenodiol, 375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodiol, 375 mg/d
Study: 30678674
Drug: Problem-solving cognitive
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving cognitive behaviour therapy (PSCBT) plus treatment as usual (TAU)
Study: 30052729
Drug: Avelumab 10mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab 10mg/kg by intravenous infusion every 2 weeks
Study: 30052729
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice of chemotherapy (paclitaxel 80mg/m2 on days 1, 8, and 15 or irinotecan 150mg/m2 on days 1 and 15)
Study: 23627026
Drug: Kurarinol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kurarinol (600 mg intravenous drip once a day for one month, followed by 200 mg oral capsule three times a day)
Study: 23627026
Drug: Silybin meglumine
Normalized name: silybin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silybin meglumine tablet (same dosage as treatment group)
Study: 17870226
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose levels in quartile I (QI) 100 mg/dl
Study: 17870226
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose levels in quartile II (QII) 130 mg/dl
Study: 17870226
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose levels in quartile III (QIII) 162 mg/dl
Study: 17870226
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose levels in quartile I (QI) 100 mg/dl after adjustment for confounders
Study: 17870226
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose levels in quartile II (QII) 130 mg/dl after adjustment for confounders
Study: 17870226
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose levels in quartile III (QIII) 162 mg/dl after adjustment for confounders
Study: 12458653
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg + HCTZ 12.5 mg
Study: 12458653
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg + HCTZ 25 mg
Study: 12458653
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg + other antihypertensive +/- HCTZ (12.5 or 25 mg)
Study: 8724536
Drug: 5-day intravenous
Normalized name: ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-day intravenous infusions of 2-CdA
Study: 8724536
Drug: intermittent 2-hour
Normalized name: CATHETER,INTERMITTENT 14FR H #94144
Approvals — FDA: no, EMA: no, PMDA: no
Description: intermittent 2-hour infusions of 2-CdA
Study: 8724536
Drug: continuous 24-hour
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous 24-hour infusion of 2-CdA
Study: 1770128
Drug: Intranasal buserelin
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal buserelin 200 micrograms four hourly for 21 days
Study: 1770128
Drug: Subcutaneous buserelin
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous buserelin 500 micrograms twice a day for 7 days, followed by 500 micrograms daily for 14 days
Study: 1770128
Drug: Subcutaneous buserelin
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous buserelin 500 micrograms three times a day for 7 days
Study: 6761186
Drug: Aspirin 330
Normalized name: aspirin 330 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 330 mg + Dipyridamole 75 mg three times daily
Study: 29796934
Drug: Allogenic bone
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogenic bone marrow-derived mesenchymal stromal cells (BM-MSCs) by intrathecal infusion (1×10^6 cells/kg body weight, four infusions once a week)
Study: 28973311
Drug: Stereotactic radiosurgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic radiosurgery (SRS) with bevacizumab, prescribed dose escalated from 18 to 22 Gy, single dose of bevacizumab given prior to SRS and continued until progression.
Study: 17071161
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (once-weekly, 45-minute stretching sessions)
Study: 11823389
Drug: Continued antidepressants
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued antidepressants before surgery (Group A, n=40)
Study: 11823389
Drug: Discontinued antidepressants
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued antidepressants 72 hr before surgery (Group B, n=40)
Study: 1971991
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) (3.4 g/d)
Study: 1971991
Drug: Linoleic acid
Normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linoleic acid (14.3 g/d)
Study: 1971991
Drug: Alpha-linolenic acid
Normalized name: Alpha-linolenic Acid
DrugBank: alpha-Linolenic acid (DB00132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-linolenic acid (9.2 g/d)
Study: 375690
Drug: Zinc sulfate,
Normalized name: Zinc sulfate, anhydrous
DrugBank: Zinc sulfate (DB09322)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc sulfate, 0.2 g three times daily
Study: 28675897
Drug: Self-monitoring of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-monitoring of daily lifestyle
Study: 19686525
Drug: Slow-release oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release oral morphine (SROM) and Methadone
Study: 8627437
Drug: Investigational pneumococcal
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational pneumococcal conjugate vaccine
Study: 8627437
Drug: Licensed pneumococcal
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed pneumococcal polysaccharide vaccine (given as a booster)
Study: 8627437
Drug: Licensed pneumococcal
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed pneumococcal polysaccharide vaccine (given as a primary injection to control group)
Study: 6324710
Drug: Cimetidine (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1,200 mg/day orally)
Study: 6324710
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg/day orally)
Study: 6324710
Drug: Warfarin sodium
Normalized name: Warfarin Sodium
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin sodium (1.5 mg/kg)
Study: 22782416
Drug: Fluorouracil plus
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil plus folinic acid (20 mg/m2 of folinic acid via IV bolus followed by 425 mg/m2 of fluorouracil via IV bolus, administered 1 to 5 days every 28 days)
Study: 22782416
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m2 IV infusion once a week for 3 of every 4 weeks for 6 months)
Study: 16829196
Drug: Oral cryotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cryotherapy (holding ice cubes in the oral cavity before, during, and after 5FU infusion)
Study: 22967016
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oral cryotherapy)
Study: 2368892
Drug: Lignocaine 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 2% with adrenaline 1:200,000 plus normal saline 0.01 ml/kg
Study: 25776532
Drug: Early, goal-directed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early, goal-directed therapy (EGDT) - a 6-hour resuscitation protocol
Study: 21853765
Drug: Traditional pharmacotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional pharmacotherapy (Fluoxetine 20 mg)
Study: 11336164
Drug: IL‐1beta (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐1beta (10 ng/ml)
Study: 11336164
Drug: ALLN (proteasome
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALLN (proteasome and NF‐kappaB activation inhibitor)
Study: 30581161
Drug: Prophylactic entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic entecavir (ETV) before chemotherapy and at least 6 months after completion of chemotherapy
Study: 23150919
Drug: Bendamustine 90
Normalized name: bendamustine 90 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine 90 mg/m² plus Bortezomib 1.0 mg/m²
Study: 23150919
Drug: Bendamustine 50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine 50, 70, or 90 mg/m² plus Bortezomib 1.0 mg/m²
Study: 21214899
Drug: Exhale® Drug‐Eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exhale® Drug‐Eluting Stent
Study: 18957146
Drug: Lung recruitment
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung recruitment maneuvers (RMs) performed twice daily for 3 days, starting at 35 cm H(2)O for 20 seconds, with potential increases to 40 cm H(2)O and 45 cm H(2)O or longer durations (30 seconds, then 40 seconds) if needed.
Study: 16581613
Drug: Antioxidants (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants (combination tablet of vitamins A, C, and E)
Study: 8624267
Drug: 5-fluorouracil 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil 500 mg m‐2, epidoxorubicin 120 mg m‐2, cyclophosphamide 500 mg m‐2 (FE120C) administered at 21 day intervals without haematopoietic growth factors
Study: 1361718
Drug: Beta-adrenergic blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenergic blocker treatment
Study: 1676594
Drug: Atracurium 0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.45 mg kg‐1
Study: 27387971
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl (2 μg/kg; maximum, 100 μg)
Study: 27387971
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (0.1 mg/kg; maximum, 8 mg)
Study: 29652460
Drug: Computer-controlled injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-controlled injection system
Study: 25899007
Drug: OBE001 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBE001 600 mg/day
Study: 25899007
Drug: Betamethasone 12
Normalized name: Betamethasone 120 microgram/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone 12 mg/day
Study: 25899007
Drug: OBE001 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBE001 and Betamethasone combination
Study: 21904204
Drug: Peginterferon α‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon α‐2a (40 KD) 180 µg/week plus ribavirin (800 mg/day) for 24 weeks
Study: 21904204
Drug: Peginterferon α‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon α‐2a (40 KD) 180 µg/week plus ribavirin (1000/1200 mg/day) for 48 weeks
Study: 21904204
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with peginterferon α‐2a (40 KD) plus ribavirin
Study: 17220050
Drug: Clopidogrel (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (single oral dose) under fed condition (after a standardized high fat breakfast)
Study: 17220050
Drug: Clopidogrel (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (single oral dose) under fasted condition
Study: 17220050
Drug: Clopidogrel (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (single oral dose) under fed condition
Study: 9088811
Drug: Esmolol 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 4.0 mg kg‐1
Study: 1768544
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate 40 mg kg‐1
Study: 9088811
Drug: Lignocaine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 1.5 mg kg‐1
Study: 7515193
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 10(6) KIU aprotinin (1 x 10(6) as a loading dose before cardiopulmonary bypass, 1 x 10(6) in the priming volume and 2.5 x 10(5)/hour intraoperatively)
Study: 7515193
Drug: Aprotinin (reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (reduced dosage)
Study: 29737802
Drug: Cinnamon (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon (3 capsules of 500 mg each daily for 8 weeks)
Study: 25346054
Drug: Placebo session
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo session (deceptive instructions regarding administration of an analgesic drug)
Study: 15685254
Drug: Tamoxifen ('Nolvadex')
Normalized name: tamoxifen Oral Tablet [Nolvadex]
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen ('Nolvadex') 20 mg/day
Study: 15685254
Drug: Anastrozole ('Arimidex')
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole ('Arimidex') 1 mg/day
Study: 9433653
Drug: Grepafloxacin 400
Normalized name: grepafloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grepafloxacin 400 mg, daily for 7 days
Study: 3803106
Drug: Urecholine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urecholine (oral or subcutaneous)
Study: 12920411
Drug: Mirtazapine (30‐45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (30‐45 mg/d)
Study: 12920411
Drug: Sertraline (50‐150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50‐150 mg/d)
Study: 12920411
Drug: Mirtazapine and
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirtazapine and Sertraline
Study: 10843485
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) with non-conjugated estrogens, mean duration of HRT was 25 months, starting on average 18 months after completed therapy for ovarian cancer.
Study: 7509399
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1:100,000 adrenaline and 5% ethanolamine injection
Study: 26341547
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 200 μg beclomethasone dipropionate (BDP) in standard posture
Study: 26341547
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 200 μg beclomethasone dipropionate (BDP) in forward leaning posture
Study: 24083590
Drug: HHPG‐19K 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: HHPG‐19K 60 μg/kg/day
Study: 24083590
Drug: HHPG‐19K 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: HHPG‐19K 100 μg/kg/day
Study: 24083590
Drug: HHPG‐19K 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: HHPG‐19K 200 μg/kg/day
Study: 24083590
Drug: Filgrastim (G‐CSF)
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim (G‐CSF) 5 μg/kg/day
Study: 21982667
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg/day
Study: 21982667
Drug: High-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose clopidogrel 150 mg/day
Study: 21511219
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg/day (in carriers of CYP2C19*2)
Study: 21511219
Drug: High-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose clopidogrel 150 mg/day (in carriers of CYP2C19*2)
Study: 21511219
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg/day (in noncarriers of CYP2C19*2)
Study: 21511219
Drug: High-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose clopidogrel 150 mg/day (in noncarriers of CYP2C19*2)
Study: 11831540
Drug: Retigabine (200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retigabine (200, 400, 500, and 600 mg per day fixed doses; 700 mg per day titrated doses)
Study: 11831540
Drug: Retigabine (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retigabine (titrated doses up to 700 mg per day)
Study: 11831540
Drug: Retigabine (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retigabine (multiple doses)
Study: 9702467
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg bd)
Study: 2405291
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin (IVIg)
Study: 20939913
Drug: Program led
Approvals — FDA: no, EMA: no, PMDA: no
Description: Program led by a clinical pharmacist trained in motivational interviewing‐based behavioral counseling approaches and authorized to make BP medication changes
Study: 18632838
Drug: Headgear (HG)
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Hydro-Tussin HG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Headgear (HG) treatment initiated immediately
Study: 12755838
Drug: Post-operative transarterial
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative transarterial chemotherapy
Study: 9065253
Drug: Daily changing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily changing of ventilation tubes
Study: 9065253
Drug: Infusion sets
Normalized name: INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion sets changed daily
Study: 9065253
Drug: Drugs for
Normalized name: DRUGS FOR CONSTIPATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs for the prevention of stress ulcers
Study: 6148312
Drug: Bopindolol (1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bopindolol (1-4 mg once daily)
Study: 6148312
Drug: Propranolol (40-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40-120 mg t.i.d.)
Study: 23324133
Drug: Concurrent medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent medical and chiropractic care
Study: 27644138
Drug: ε-caprolactam concentration
Normalized name: N-dodecyl-.epsilon.-caprolactam
DrugBank: Laurocapram (DB17308)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ε-caprolactam concentration of 0.05 mg/m³
Study: 27644138
Drug: ε-caprolactam concentration
Normalized name: N-dodecyl-.epsilon.-caprolactam
DrugBank: Laurocapram (DB17308)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ε-caprolactam concentration of 0.5 mg/m³
Study: 27644138
Drug: ε-caprolactam concentration
Normalized name: N-dodecyl-.epsilon.-caprolactam
DrugBank: Laurocapram (DB17308)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ε-caprolactam concentration of 5.0 mg/m³
Study: 27644138
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (0.0 mg/m³)
Study: 19123874
Drug: Shirodhara treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shirodhara treatment
Study: 15927409
Drug: Immediate concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate concurrent chemoradiation (cisplatin-based) with short overall treatment time (completed within 5 days of plan)
Study: 15927409
Drug: Immediate concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate concurrent chemoradiation (cisplatin-based) with prolonged treatment time (protocol violation)